Anil Goyal

Dr. Goyal, has 24+ years of senior management and leadership experience at several public and private biotechnology companies where he has raised more than $200 million from public/private investors/federal sources, completed more than $1billion in pharma deals and accomplished several exits. He is currently Chairman and CEO of IMMvention Therapeutix, a company developing novel disease modifying therapies based on pan-inflammasome inhibition for rare and prevalent auto-inflammatory diseases. Prior to IMMvention, at Ribometrix he raised first venture funding round. His experience includes, leading company formation, fund raising, business development, M&A, strategic planning, and senior management roles at Heat Biologics (HTBX), Serenex (led acquisition/sale to Pfizer), Optherion (led acquisition/sale to Sequenom and Baxter), Qualiber, Ascletis (public company on Hong Kong market) and Millennium Pharmaceuticals (acquired by Takeda). In addition to his senior management roles at companies, he has founded OpenDoors Group, a consulting practice to serve as advisor and board member to biotech companies on help execute fund raising, business development, M&A, growth and exit strategies. Dr. Goyal received his Ph.D. degree in Microbiology and Molecular Genetics jointly from Rutgers, The State University and University of Medicine and Dentistry of New Jersey.